What Is Mast Cell Activation Syndrome?

Mast cell activation syndrome (MCAS) is a condition in which mast cells — immune cells found in connective tissues throughout the body — become hyperreactive, releasing their chemical mediators (histamine, tryptase, prostaglandins, leukotrienes, and cytokines) excessively and inappropriately. The result is a bewildering array of symptoms affecting multiple organ systems, often with no apparent trigger or a response to stimuli that should not provoke a reaction.

MCAS is increasingly recognised as a significant source of chronic, unexplained symptoms. Its prevalence is estimated at up to 17% of the population, though many cases remain undiagnosed because the symptoms are diffuse and overlap with numerous other conditions.

Why the Gut Is Central to MCAS

The gastrointestinal tract contains the highest concentration of mast cells in the body. This makes biological sense: the gut is the largest interface between the body and the external environment, and mast cells serve as sentinel immune cells that respond to perceived threats. In MCAS, these sentinel cells are on a hair trigger.

GI Symptoms of MCAS

Gastrointestinal symptoms are present in 60-80% of MCAS patients and are often the predominant complaint:

  • Abdominal pain and cramping — often diffuse and migratory
  • Diarrhoea and/or constipation — alternating patterns are common
  • Severe bloating and distension
  • Nausea — sometimes severe and persistent
  • Gastroesophageal reflux — mast cell mediators relax the lower esophageal sphincter
  • Multiple food sensitivities — reacting to a wide and seemingly random array of foods
  • Early satiety — feeling full quickly due to impaired gastric accommodation

Non-GI Symptoms

MCAS affects the entire body because mast cells are distributed throughout all tissues:

  • Skin — flushing, hives, itching, angioedema, dermatographia (skin writing)
  • Neurological — headaches, brain fog, anxiety, insomnia, neuropathic pain
  • Cardiovascular — tachycardia, blood pressure instability, presyncope
  • Respiratory — wheezing, nasal congestion, throat tightness
  • Musculoskeletal — diffuse pain, joint hypermobility (MCAS frequently co-occurs with Ehlers-Danlos syndrome)
A hallmark of MCAS is symptoms that seem too numerous and too varied to be one condition. If you have been told "it cannot all be connected" by multiple specialists, MCAS should be considered. In MCAS, everything is connected through the common pathway of mast cell mediator release.

The Gut-Mast Cell Feedback Loop

MCAS and gut dysfunction create a self-amplifying cycle:

  • Gut dysbiosis activates mast cells — bacterial products, particularly LPS from gram-negative bacteria, directly trigger mast cell degranulation through TLR4 receptors
  • Mast cell mediators damage the gut barrier — histamine and tryptase increase intestinal permeability by degrading tight junction proteins
  • Increased permeability increases antigen exposure — more food proteins and bacterial products cross the barrier, encountering more mast cells in the lamina propria
  • Activated mast cells alter motility — histamine and prostaglandins disrupt normal gut motility, promoting SIBO, which further activates mast cells

Breaking this cycle requires addressing both the mast cell hyperreactivity and the underlying gut dysfunction simultaneously.

Diagnosis of MCAS

MCAS diagnosis requires meeting three criteria:

  • Chronic or recurrent symptoms consistent with mast cell mediator release affecting two or more organ systems
  • Laboratory evidence of mast cell mediator elevation (serum tryptase, urinary N-methylhistamine, urinary prostaglandin D2 metabolites, or urinary leukotriene E4)
  • Symptom improvement with mast cell-targeted medications

Testing is notoriously tricky. Mediator levels can be normal between episodes, and samples must be handled carefully (chilled and processed rapidly). Repeated testing during symptomatic episodes increases diagnostic yield.

Gut-Focused MCAS Management

Stabilise the Gut Barrier

Reducing intestinal permeability decreases the antigen load that triggers mast cell activation. L-glutamine, zinc carnosine, omega-3 fatty acids, and quercetin all support barrier repair. Quercetin deserves special mention as it is both a mast cell stabiliser and a gut barrier supporter.

Address SIBO and Dysbiosis

If SIBO is present (common in MCAS), treatment reduces the bacterial triggers for mast cell activation. Use microbiome-supportive antimicrobials and prokinetics under practitioner guidance.

Low-Histamine Diet as a Starting Point

A temporary low-histamine diet reduces the total mediator burden. This is not about identifying allergens; it is about lowering the baseline so the mast cells are less reactive. Foods to avoid include aged cheeses, fermented foods (during the stabilisation phase), alcohol, cured meats, and leftover foods.

Mast Cell Stabilisers and Antihistamines

Pharmaceutical options include H1 antihistamines (cetirizine, loratadine), H2 antihistamines (famotidine), mast cell stabilisers (cromolyn sodium, ketotifen), and leukotriene receptor antagonists (montelukast). These are often used in combination and titrated to the individual's response.

MCAS is a condition where the gut-immune connection is impossible to ignore. GutIQ evaluates the digestive and immune-related symptom patterns that may point toward mast cell involvement, helping you and your practitioner identify whether MCAS could be driving your symptoms.